Your cart is currently empty!
AlphaThera was awarded an SBIR Phase II grant by the NIH/NCI to further development of ADCs generated by proximity-based sortase-mediated ligation.
The TABA supplemental funding will go directly towards supporting scaled commercialization activities of AlphaThera’s site-specific antibody labeling technology.
AlphaThera was awarded a grant to research & commercialize conjugation technologies that will assist in scale-up of COVID-19 serological assays to meet demand for daily testing.
AlphaThera was awarded an NIH Grant for research into Trim21-mediated degradation of antibody-targeted cytosolic proteins.
AlphaThera was awarded an NHI/NHLBI Grant to fund research for Photoreactive Antibody-Binding Domain-Microccocal Nuclease Conjugates ((pAbBD)-MNase).
AlphaThera was awarded an NIH Phase II Grant for continued research into site-specific labeling and immobilization of antibodies for immunoassays.
AlphaThera awarded a grant by the NIH/NCI to fund research for Site-specific Antibody-Drug Conjugates by proximity-based sortase ligation.
AlphaThera was awarded an NIH/NIBIB Grant to fund research for designing Tools for Site-Specific Antibody Immobilization for Immunoassays.
AlphaThera’s co-founder, Dr. Andrew Tsourkas, was featured in a speaker event “Moving Ideas to Market: A Discussion with Entrepreneurs & Researchers” hosted by Penn Center for Innovation
Pennovation Works featured a product spotlight for AlphaThera’s oYo-Link™ Oligo Custom conjugation product.
Joe Fetterman of Colliers LabNotes interviews AlphaThera co-founder Dr. Andrew Tsourkas about his backstory & path toward founding AlphaThera.
UPenn’s prominent independent newspaper, the Daily Pennsylvanian, featured an article about AlphaThera’s recent COVID-19 grant award.
AlphaThera has announced the further expansion of its distributor network as interest in their oYo-Link Site Specific Antibody Labeling Technology continues to grow on an international scale.
AlphaThera has teamed up with Quartzy to make their oYo-Link Antibody labeling products conveniently available to researchers for purchase.
AlphaThera has announced a distribution agreement with Funakoshi Co., Ltd. to deliver oYo-Link® Antibody labeling products to researchers in Japan.
For the efficient removal of free oYo-Link® post conjugation AlphaThera has announced the launch of oYo-Capture™ Magnetic Beads, providing researchers with an efficient method of removing free oYo-Link® reagents post antibody conjugation to ensure low background in high sensitivity assays. AlphaThera is well known within the life science research community for their oYo-Link® antibody labeling […]
AlphaThera has announced the launch of oYo-Link® Horseradish Peroxidase (HRP), the latest addition to their range of site-specific antibody labeling reagents. The oYo-Link antibody-HRP labeling technology will enable the rapid production of highly uniform primary antibody conjugates in under two hours, and with only 30 seconds hands-on time.
AlphaThera have announced the addition of DM4 to their range of oYo-Link® Antibody-Drug Conjugation Reagents which also includes VcMMAE, VcMMAF and DM1.
AlphaThera has announced the launch of oYo-Link® Epitope Tag, the latest addition to their range of site-specific antibody labeling reagents.
Dr. Andrew Tsourkas and Dr. Feifan Yu interview about oYo-Link Oligo technology and its potential within the field of multi-omic single-cell analysis.
AlphaThera members & Penn researchers worked to publish a high-impact publication in Bioconjugate Chemistry titled “Efficient Labeling of Native Human IgG by Proximity-Based Sortase-Mediated Isopeptide Ligation”.
Read how a research team used AlphaThera’s site-specific bioconjugation technique to seed nanoparticles with a TGFa payload.
A layman’s summary of AlphaThera’s LASIC site-specific Antibody labeling technology was published by the Atlas of Science.